Pipeline

AL Amyloidosis and autoimmune CAR-T Company with 76 patients dosed to-date

Our Clinical Trials

Our lead candidate is NXC-201, a BCMA-targeted CAR-T NXC-201 in Phase 1b/2a clinical trials (NEXICART-1 – NCT04720313) in relapsed/refractory AL Amyloidosis and relapsed/refractory multiple myeloma which has treated 72 patients

Our tissue specific therapeutic IMX-110 is currently in clinical trials as a monotherapy, and in combination with tislelizumab (BeiGene anti-PD-1 – IMMINENT-01 NCT05840835) for advanced solid tumors which has treated 30 patients

NXC-201 CELL THERAPY PUBLICATIONS

IMX-110 Mechanism of Action